Drugs in ContextPasireotide-LAR is recommended as a second-line treatment for patients with acromegaly. Although the effects of pasireotide-LAR have been well characterized in clinical studies, real-practice evidence is scant, especially in the long term and within the ...
Sabrina Chiloiro +12 more
doaj +3 more sources
Long-term, real-world experience of pasireotide dose reduction in patients with acromegaly [PDF]
Endocrine Connections, 2023 Pasireotide long-acting release is effective in achieving bioche mical control and reducing tumour volume in patients with acromegaly inadequately controll ed by first-line therapy.
Nelma Veronica Marques +2 more
doaj +3 more sources
Pasireotide-induced hyperglycemia in Cushing’s disease and Acromegaly: A clinical perspective and algorithms proposal [PDF]
Frontiers in EndocrinologyPasireotide is an effective treatment for both Cushing’s disease (CD) and acromegaly due to its ability to suppress adrenocorticotropic hormone and growth hormone, and to normalize insulin-like growth factor-1 levels, resulting in tumor shrinkage ...
Przemysław Witek +3 more
doaj +3 more sources
Real-Life Data on the Safety of Pasireotide in Acromegaly: Insights from EudraVigilance. [PDF]
Pharmaceuticals (Basel)Background/Objectives: Pasireotide (PAS) is a somatostatin receptor ligand (SRL) used to treat acromegaly, a chronic condition caused by excess growth hormone.
Popa Ilie IR +8 more
europepmc +3 more sources
Successful debulking of plurihormonal pituitary macroadenoma with long‐acting pasireotide and dopamine agonist combination therapy [PDF]
Clinical Case Reports, 2019 Key Clinical Message Long‐acting pasireotide and bromocriptine provided biochemical control of growth hormone and prolactin in a patient with plurihormonal pituitary macroadenoma, allowing near‐complete tumor excision while restoring pituitary function ...
Terri W. Jerkins +2 more
doaj +2 more sources
Frontiers in Endocrinology, 2023 ObjectiveThis study evaluated short- and long-term efficacy and safety of the second-generation somatostatin receptor ligand pasireotide alone or in combination with dopamine agonist cabergoline in patients with Cushing’s disease (CD).Study designThis is
Richard A. Feelders +13 more
doaj +2 more sources
Pasireotide—a novel somatostatin receptor ligand after 20 years of use [PDF]
Reviews in Endocrine & Metabolic Disorders, 2022 Pasireotide, a novel multireceptor-targeted somatostatin receptor ligand (SRL) is characterized by a higher affinity to somatostatin receptor type 5 than type 2, unlike first-generation SRLs.
Marek Bolanowski +3 more
openalex +2 more sources
Frontiers in EndocrinologyPasireotide is a somatostatin analogue for the treatment of acromegaly, a chronic condition caused by excess growth hormone. Despite the therapeutic benefits of pasireotide as a second-line treatment for inadequately controlled acromegaly, a major ...
Sylvère Störmann +8 more
doaj +2 more sources
Cost-effectiveness analysis of second-line medical therapies in acromegaly: a real-life study [PDF]
Frontiers in EndocrinologyIntroductionAcromegaly is an uncommon disease with important comorbidity and economic cost. Although the pharmacological cost of second-line treatment for refractory acromegaly has been theoretically analyzed, real-life studies are needed.ObjectivesTo ...
Eva Venegas Moreno +12 more
doaj +2 more sources
Insights into GLP-1 and insulin secretion mechanisms in pasireotide-induced hyperglycemia highlight effectiveness of Gs-targeting diabetes treatment [PDF]
Scientific ReportsPasireotide frequently causes severe hyperglycemia; however, its detailed mechanism remains unknown. There are no published guidelines regarding the optimal management of pasireotide-induced hyperglycemia based on its pathophysiology.
Junichiro SATO +8 more
doaj +2 more sources